Study of MTX-463 for Idiopathic Pulmonary Fibrosis
Part of Lungs & breathing clinical trials.
This trial tests an experimental drug called MTX-463 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if targeting a protein called WISP1 can slow lung scarring and help you breathe better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 40 years old.
- You were diagnosed with IPF within the last 7 years.
- Your lung function (FVC) is at least 45% of normal and your ability to transfer oxygen (DLCO) is at least 25%.
- You are not on continuous oxygen and do not smoke or vape.
- If you take pirfenidone, nintedanib, or nerandomilast, your dose has been stable for at least 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, BI 765423, to see if it can improve lung function in people with IPF, a lung scarring disease. You can join whether or not you are already taking standard treatments like nintedanib or pirfenidone.
This trial tests a treatment to reduce certain antibodies in the blood that may be making your idiopathic pulmonary fibrosis (IPF) worse. The goal is to slow down the progression of the disease and help you breathe easier.
This trial tests an oral medicine called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to see if the drug can help slow the disease. You may qualify if you are 40 or older, have a confirmed IPF diagnosis with certain lung function levels, and are either on a stable dose of standard IPF meds or not taking them.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This trial tests a new medication called SC1011 taken twice a day, compared to a placebo, to see if it can help people with IPF. It is for patients who were diagnosed within the last 5 years and have moderate lung function.
This study tests artesunate, a medicine that may help treat idiopathic pulmonary fibrosis (IPF), a condition that causes lung scarring. It is for people who are already taking other IPF treatments and want to see if adding artesunate can improve their condition.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.